Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2791 - Impact of the duration of diabetes mellitus (DM) on the outcomes of metastatic pancreatic cancer (mPC) treated with gemcitabine (G): a retrospective study

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancer in Special Situations;  Pancreatic Cancer

Presenters

KEN OHASHI

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

K. OHASHI1, S. Iizumi2, A. Kuchiba3, M. Ikeda4, Y. Sakamoto2, S. Kondo2, C. Morizane2, H. Ueno2, K. Osame1, S. Mitsunaga4, I. Ohno4, H. Imaoka4, Y. Hashimoto4, H. Takahashi4, M. Sasaki4, T. Okusaka2

Author affiliations

  • 1 Department Of General Internal Medicine, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Department Of Hepatobiliary And Pancreatic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Biostatistics Division, Center for Research Administration and Support, National Cancer Center, 104-0045 - Tokyo/JP
  • 4 Department Of Hepatobiliary And Pancreatic Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
More

Resources

Abstract 2791

Background

While previous studies showed that patients (pts) with PC and long-standing DM had worse survival than pts without DM, the impact of the duration of DM on therapeutic outcomes has not been sufficiently studied in pts receiving chemotherapy for mPC.

Methods

We retrospectively analyzed the therapeutic results for pts with mPC who received G as standard therapy before the introduction of combination regimens at two sites of the National Cancer Center (“Tokyo” and “Kashiwa”). The efficacies and toxicities of G were compared among three groups classified by the DM duration: no DM, short-term DM (< 4 years), and long-term DM (≥ 4 years). To examine the associations of the DM duration with overall survival (OS) and progression free survival (PFS), Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for the baseline characteristics.

Results

Overall, 350 pts (“Tokyo”: n = 202, 2008-2013; “Kashiwa”: n = 148, 2008-2011), were included: 218, 87, and 45 in the no DM, short-term DM, and long-term DM groups, respectively. No statistically significant differences in baseline characteristics were observed among the three groups except for BMI (median [kg/m2]: 20.7, 21.4, and 22.5; p = 0.015, Kruskal–Wallis test). Compared with the no DM group, multivariable-adjusted HRs for PFS were 1.33 (95% CI, 0.94-1.89; p = 0.103) for the long-term DM group and 1.12 (95% CI, 0.85-1.47; p = 0.410) for the short-term DM group; and those for OS were 1.37 (95% CI, 0.95-1.98; p = 0.096) and 1.10 (95% CI, 0.82-1.46; p = 0.533), respectively. There were no substantial differences in HRs between “Tokyo” and “Kashiwa” (e.g., HRs of long-term DM for PFS were 1.54 [95% CI, 0.98-2.44] and 1.33 [95% CI, 0.80-2.21], respectively; HRs of long-term DM for OS were 1.32 [95% CI, 0.82-2.14] and 1.34 [95% CI, 0.80-2.26], respectively). Also, HRs for PFS and OS did not substantially change with different cutoff years of DM duration (ranges of HRs of long-term DM with cutoff at 3-5 years: PFS, 1.36-1.55; OS, 1.21-1.33). No significant differences in tumor response and toxicity were observed.

Conclusions

A long pretreatment history of DM may be associated with a shorter PFS and OS among pts with mPC.

Clinical trial identification

Legal entity responsible for the study

National Cancer Center Hospital

Funding

None

Disclosure

M. Ikeda: Advisory board membership of Nano Carrier; research funding from Yakult, Taiho, Ono, Eisai, AstraZeneca, Zeria, Merck Serono, Baxter, and Nano Carrier; honoraria from Novartis, Taiho, Chugai, Daiichi Sankyo, Eli Lilly, and Yakult. S. Kondo: Research funding from Pfizer, Merck Serono, AstraZeneca, Bayer, and Eli Lilly. C. Morizane: Honoraria from Pfizer, Novartis, Yakult, Eli Lilly, and Nobelpharma; advisory role in AstraZeneca, Yakult, Novartis, and Taiho; an Immediate Family Member received honoraria from FUJIFILM RI Pharma. S. Mitsunaga: Honoraria from Ono and Toray; research funding from Bayer, Chugai, Merck Serono, ASLAN, and Ajinomoto. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.